Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on June 17, 2026. The report addresses a regulatory matter concerning the company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance rather than financial performance.
Material Changes
The primary material event is the resolution of a prior non-compliance issue. On June 27, 2025, the company received notice from Nasdaq that it failed to maintain the minimum bid price of $1.00 per share required under Listing Rule 5550(a)(2). As of June 17, 2026, Nasdaq determined that the company's closing bid price had been at or above $1.00 per share for the period between June 3, 2026, and June 16, 2026. Consequently, the company has regained compliance, and Nasdaq has closed the matter.
Guidance, Outlook, and Risks
Management announced the regained compliance via a press release issued on June 18, 2026. The filing does not contain forward-looking guidance, financial outlook, or new risk factors beyond the resolution of the specific listing deficiency. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the current trading price of SILO common stock to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the stock price recovery.
- Monitor future filings for any new notices from Nasdaq regarding listing standards.